Table 3.
Effects of teneligliptin on plasma levels of factors affecting glucose and lipoprotein metabolism
| Treatment duration (weeks) | 0 | 4 | 12 | p valuesa |
|---|---|---|---|---|
| FPG (mg/dL) | 131 (113, 163)b | 110 (98, 126) | 117 (101, 127) | 0.0015 |
| HbA1c (%) | 6.6 (5.7, 7.7) | 6.2 (5.6, 7.1) | 6.0 (5.4, 6.4) | 0.0011 |
| C-peptide (ng/mL) | 6.1 (5.5, 8.1) | 7.2 (5.6, 9.0) | 6.9 (5.8, 7.8) | 0.5749 |
| TC (mg/dL) | 186 (136, 202) | 150 (140, 202) | 148 (131, 176) | 0.4244 |
| TG (mg/dL) | 149 (103, 176) | 119 (69, 170) | 129 (97, 149) | 0.1238 |
| LDL-C (mg/dL) | 84 (67, 115) | 88 (74, 104) | 74(63, 99) | 0.3614 |
| HDL-C (mg/dL) | 40 (35, 46) | 37 (34, 44) | 33 (30, 45) | 0.4640 |
| RLP-C (mg/dL) | 12.5 (6.1, 13.7) | 10.8 (4.7, 13.8) | 8.1 (5.7, 11.4) | 0.0171 |
| Apo B (mg/dL) | 98 (65, 108) | 84 (65, 109) | 76 (61, 92) | 0.1454 |
| Ox-LDL (U/L) | 83 (79, 99) | 81 (63, 86) | 75 (43, 104) | 0.4640 |
| LPL (ng/mL) | 61 (49, 83) | 51 (48, 73) | 69 (50, 80) | 0.4169 |
| LDL-C/apo B ratio | 1.06 (0.93, 1.12) | 1.10 (0.90, 1.13) | 1.07 (0.94, 1.13) | 0.7123 |
apo B apolipoprotein B, C cholesterol, FPG fasting plasma glucose, HbA1c glycated hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, LPL lipoprotein lipase, Ox oxidized, RLP remnant-like particle, TC total cholesterol, TG triglyceride
aStatistical significance by Friedman test; p < 0.05 was considered as significant
bMedian (25 and 75 percentile)